KDR overexpression	Glioblastoma	KDR overexpression	Glioblastoma	bevacizumab + erlotinib Resistant: C3 – Early Trials bevacizumab + erlotinib Resistant : C3	bevacizumab + erlotinib Resistant: C3 – Early Trials bevacizumab + erlotinib Resistant : C3
KDR overexpression	Hepatocellular Cancer	KDR overexpression	Hepatocellular Cancer	bevacizumab + atezolizumab Sensitive: C3 – Early Trials bevacizumab + atezolizumab Sensitive : C3	bevacizumab + atezolizumab Sensitive: C3 – Early Trials bevacizumab + atezolizumab Sensitive : C3
KDR overexpression	Glioblastoma	KDR overexpression	Glioblastoma	bevacizumab Resistant: C3 – Early Trials bevacizumab Resistant : C3	bevacizumab Resistant: C3 – Early Trials bevacizumab Resistant : C3
KDR overexpression	Osteosarcoma	KDR overexpression	Osteosarcoma	anlotinib Sensitive: C3 – Early Trials anlotinib Sensitive : C3	anlotinib Sensitive: C3 – Early Trials anlotinib Sensitive : C3
KDR overexpression	Non Small Cell Lung Cancer	KDR overexpression	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KDR overexpression	Non Small Cell Lung Cancer	KDR overexpression	Non Small Cell Lung Cancer	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3
KDR overexpression	Nasopharyngeal Carcinoma	KDR overexpression	Nasopharyngeal Carcinoma	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3
KDR overexpression	Breast Cancer	KDR overexpression	Breast Cancer	sunitinib Sensitive: C4 – Case Studies sunitinib Sensitive : C4	sunitinib Sensitive: C4 – Case Studies sunitinib Sensitive : C4
KDR overexpression	Renal Cell Carcinoma	KDR overexpression	Renal Cell Carcinoma	sunitinib Sensitive: D – Preclinical sunitinib Sensitive : D	sunitinib Sensitive: D – Preclinical sunitinib Sensitive : D

KDR overexpression

Associations